MedTrace Logo

Double Randomized and Placebo Controlled Trail of Tianqi Pingchan Granule to Prevent Levodopa-Induced Dyskinesia

NCT04173845 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2019-11-22

No results posted yet for this study

Summary

A randomized, double-blind, placebo-controlled multicenter clinical trial was used to observe the effectiveness, safety and side effects of Tianqi Pingzhan Granule in the prevention of levodopa induced dyskinesia, so as to determine the clinical efficacy of Tianqi Pingzhan Granule in the prevention of levodopa induced dyskinesia.

Conditions

  • Levodopa-Induced Dyskinesia

Interventions

DRUG

Tianqi Pingchan Granule

Tianqi Pingchan Granule are given twice a day

DRUG

Tianqi Pingchan Granule Placebo

Tianqi Pingchan Granule Placebo

Sponsors & Collaborators

  • Affiliated Hospital of Nanjing University of Chinese Medicine

    collaborator OTHER

  • Xin Hua Hospital of Zhejiang Province

    collaborator OTHER

  • Suqian Branch, Jiangsu Province Hospital

    collaborator UNKNOWN

  • Huai'an First People's Hospital

    collaborator OTHER

  • Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

    lead OTHER

Principal Investigators

  • Zhenguo Liu, MD · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-01
Primary Completion
2020-12-31
Completion
2021-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04173845 on ClinicalTrials.gov